Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury

[1]  S. Fulda,et al.  Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells , 2017, Oncogene.

[2]  M. Pasparakis,et al.  Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis , 2016, Nature.

[3]  J. Muntané,et al.  Modulation of Autophagy by Sorafenib: Effects on Treatment Response , 2016, Front. Pharmacol..

[4]  N. van Bruggen,et al.  RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury , 2016, Cell Death and Differentiation.

[5]  A. Degterev,et al.  Generation of small molecules to interfere with regulated necrosis , 2016, Cellular and Molecular Life Sciences.

[6]  Chuan-Yuan Li,et al.  Key roles of necroptotic factors in promoting tumor growth , 2016, Oncotarget.

[7]  J. Murphy,et al.  HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death , 2016, Cell Death and Disease.

[8]  James M. Murphy.  Faculty Opinions recommendation of Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. , 2015 .

[9]  M. Bertrand,et al.  NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling. , 2015, Molecular cell.

[10]  S. Fulda,et al.  Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. , 2015, Cancer letters.

[11]  J. Park.  Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy , 2015, Clinical and molecular hepatology.

[12]  K. Kehn-Hall,et al.  Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection , 2015, Front. Microbiol..

[13]  G. Superti-Furga,et al.  A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis , 2015, Cell Death and Disease.

[14]  Xiaodong Wang,et al.  A cytosolic heat shock protein 90 and cochaperone CDC37 complex is required for RIP3 activation during necroptosis , 2015, Proceedings of the National Academy of Sciences.

[15]  K. Schmid,et al.  Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status , 2015, BMC Cancer.

[16]  J. Bertin,et al.  Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. , 2015, Cell reports.

[17]  G. Santoni,et al.  Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells , 2015, Oncoscience.

[18]  A. Anel,et al.  Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis , 2015, Clinical and Translational Oncology.

[19]  P. Vandenabeele,et al.  Necroptosis and its role in inflammation , 2015, Nature.

[20]  Kenta Moriwaki,et al.  RIP3 induces apoptosis independent of pronecrotic kinase activity. , 2014, Molecular cell.

[21]  B. Stockwell,et al.  Regulated cell death and inflammation: an auto-amplification loop causes organ failure , 2014, Nature Reviews Immunology.

[22]  W. Alexander,et al.  Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death , 2014, Proceedings of the National Academy of Sciences.

[23]  M. Andreeff,et al.  Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia , 2014, Expert opinion on investigational drugs.

[24]  S. Strittmatter,et al.  Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks , 2014, Nature Medicine.

[25]  Z. Miao,et al.  The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury , 2014, Cell Death and Disease.

[26]  M. Bertrand,et al.  MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. , 2014, Cell reports.

[27]  Xiaodong Wang,et al.  Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. , 2014, Molecular cell.

[28]  L. Komuves,et al.  Activity of Protein Kinase RIPK3 Determines Whether Cells Die by Necroptosis or Apoptosis , 2014, Science.

[29]  P. Vandenabeele,et al.  Regulated necrosis: the expanding network of non-apoptotic cell death pathways , 2014, Nature Reviews Molecular Cell Biology.

[30]  C. Trautwein,et al.  Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo , 2014, Cell Death and Disease.

[31]  Jiahuai Han,et al.  Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death , 2013, Cell Research.

[32]  Ling-gang Wu,et al.  Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis , 2013, Nature Cell Biology.

[33]  Michelle C. Schaeffer,et al.  Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. , 2013, ACS medicinal chemistry letters.

[34]  S. Fulda,et al.  Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis , 2013, Cell Death and Disease.

[35]  P. Vandenabeele,et al.  RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition , 2013, Cell Death and Differentiation.

[36]  D. Green,et al.  Two independent pathways of regulated necrosis mediate ischemia–reperfusion injury , 2013, Proceedings of the National Academy of Sciences.

[37]  Peter Vandenabeele,et al.  Determination of apoptotic and necrotic cell death in vitro and in vivo. , 2013, Methods.

[38]  Yigong Shi,et al.  Structural basis of RIP1 inhibition by necrostatins. , 2013, Structure.

[39]  Peter Vandenabeele,et al.  Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. , 2013, Immunity.

[40]  A. Tessitore,et al.  The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages , 2012, BioMed research international.

[41]  P. Vandenabeele,et al.  Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models , 2012, Cell Death and Disease.

[42]  Han‐Chieh Lin,et al.  Rho‐kinase–dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[43]  U. Kunzendorf,et al.  Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. , 2012, Kidney international.

[44]  D. Strumberg.  Sorafenib for the treatment of renal cancer , 2012, Expert opinion on pharmacotherapy.

[45]  Xiaodong Wang,et al.  Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase , 2012, Cell.

[46]  T. Vanden Berghe,et al.  RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. , 2011, Immunity.

[47]  Vanesa Fernández-Majada,et al.  FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation , 2011, Nature.

[48]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[49]  R. Hakem,et al.  RIP3 mediates the embryonic lethality of caspase-8-deficient mice , 2011, Nature.

[50]  Guy S. Salvesen,et al.  Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis , 2011, Nature.

[51]  P. Vandenabeele,et al.  Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.

[52]  Giuseppe Palmieri,et al.  HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. , 2010, Clinical immunology.

[53]  J. Sanghera,et al.  Comparison of the luminescent ADP-Glo assay to a standard radiometric assay for measurement of protein kinase activity. , 2009, Assay and drug development technologies.

[54]  V. Echeverria,et al.  Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice , 2009, Neuroscience.

[55]  E. Hildt,et al.  New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication , 2009, Gut.

[56]  S. Hwang,et al.  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo , 2009, Molecular Cancer Therapeutics.

[57]  Na Zhang,et al.  RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis , 2009, Science.

[58]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Tao Wang,et al.  Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α , 2009, Cell.

[60]  F. Chan,et al.  Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation , 2009, Cell.

[61]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[62]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[63]  P. Dent,et al.  The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress , 2007, Molecular and Cellular Biology.

[64]  Alma L Burlingame,et al.  A semisynthetic epitope for kinase substrates , 2007, Nature Methods.

[65]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[66]  Peter Vandenabeele,et al.  Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. , 2006, Biochimica et biophysica acta.

[67]  Gabriel Pineda,et al.  Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. , 2006, Molecular cell.

[68]  Alexei Degterev,et al.  Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury , 2005, Nature chemical biology.

[69]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[70]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[71]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[72]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[73]  T. Vanden Berghe,et al.  Disruption of HSP90 Function Reverts Tumor Necrosis Factor-induced Necrosis to Apoptosis* , 2003, The Journal of Biological Chemistry.

[74]  W. Fiers,et al.  Inhibition of Caspases Increases the Sensitivity of L929 Cells to Necrosis Mediated by Tumor Necrosis Factor , 1998, The Journal of experimental medicine.

[75]  T. Gilmore,et al.  Introduction to NF-kappaB: players, pathways, perspectives. , 2006, Oncogene.

[76]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.